Dhankhar R.,Nanomedine Research Center |
Vyas S.P.,Drug Delivery Research Laboratory |
Jain A.K.,Nanomedine Research Center |
Arora S.,Nanomedine Research Center |
And 2 more authors.
Artificial Cells, Blood Substitutes, and Biotechnology | Year: 2010
Breast cancer remains one of the world's most devastating diseases. However, better understanding of tumor biology and improved diagnostic devices could lead to improved therapeutic outcomes. Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. Recently, targeted drug delivery systems for anti-tumor drugs have demonstrated great potential to lower cytotoxicity and increase therapeutic effects. Various ligands/approaches have been explored for targeting breast cancer. This paper provides an overview of breast cancer, conventional therapy, potential of nanotechnology in management of breast cancer, and rational approaches for targeting breast cancer. © 2010 Informa Healthcare USA, Inc.
Kaur G.,Nanomedine Research Center |
Narang R.K.,Nanomedine Research Center |
Rath G.,Nanomedine Research Center |
Goyal A.K.,Nanomedine Research Center
Artificial Cells, Blood Substitutes, and Biotechnology | Year: 2012
Nanotechnology has potential in the development of novel and effective delivery of drugs within lungs. Different strategies have been utilized for pulmonary delivery of drugs, including the use of lipid-based delivery systems (liposomes, ISCOMs, SLNs), use of polymeric matrix (PLGA, poly caprolactone, cynoacrylates, gelatin), development of polysaccharide particulates (chitosan, alginates, Carbopol, etc.), biocompatible metallic inorganic particles (iron, gold, zinc), etc. This paper reviews various nanopaticulate approaches in the form of lipids, polymers, metals, polysaccharides, or emulsions based for pulmonary drug delivery that could provide an increased biological efficacy and better local and systemic action. © 2012 Informa Healthcare USA, Inc.